Return to homepagePandemic Pact

A5401 COVID Supplement

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI106701-07S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $3,770,048

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    PROFESSOR Grace Aldrovandi

  • Research Location

    United States of America

  • Lead Research Institution

    UNIVERSITY OF CALIFORNIA LOS ANGELES

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

ABSTRACT The AIDS Clinical Trials Group (ACTG) has been selected to lead a Master Adaptive protocol under the Accelerating COVID-19 Therapeutic Interventions and Vaccine (ACTIV) Operation Warp Speed. This trial (ACTG 5401 or ACTIV-2) will evaluate multiple monoclonal antibodies and other small molecules for outpatient COVID treatment. The Laboratory Center will expand its efforts to include support for COVID-19 clinical trials.